Published in Clin Immunol on July 25, 2013
Th17 cells and Tregs: unlikely allies. J Leukoc Biol (2014) 1.03
Culture models to define key mediators of cancer matrix remodeling. Front Oncol (2014) 0.81
Combining FoxP3 and Helios with GARP/LAP markers can identify expanded Treg subsets in cancer patients. Oncotarget (2016) 0.80
Chronic Recreational Physical Inactivity and Epithelial Ovarian Cancer Risk: Evidence from the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev (2016) 0.78
Critical Role for the Adenosine Pathway in Controlling Simian Immunodeficiency Virus-Related Immune Activation and Inflammation in Gut Mucosal Tissues. J Virol (2015) 0.75
TNF activity and T cells. Cytokine (2016) 0.75
Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy. Oncotarget (2016) 0.75
Treg activation defect in type 1 diabetes: correction with TNFR2 agonism. Clin Transl Immunology (2016) 0.75
Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge", Napoli, November 30th 2016. J Transl Med (2017) 0.75
Immune Cell Population in Ovarian Tumor Microenvironment. J Cancer (2017) 0.75
Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med (2003) 4.64
A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. Nat Med (2004) 2.93
Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst (2004) 2.79
Chapter 8: Screening for cervical cancer in developing countries. Vaccine (2006) 2.35
Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J Immunol (2004) 2.33
Distinct and non-redundant roles of microglia and myeloid subsets in mouse models of Alzheimer's disease. J Neurosci (2011) 2.31
A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy. Clin Cancer Res (2005) 2.24
Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer (2011) 2.09
Pathogen recognition and development of particulate vaccines: does size matter? Methods (2006) 2.09
Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. Vaccine (2002) 1.97
Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. Curr Cancer Drug Targets (2010) 1.91
IMGT/HighV QUEST paradigm for T cell receptor IMGT clonotype diversity and next generation repertoire immunoprofiling. Nat Commun (2013) 1.71
Natural regulatory T cells and persistent viral infection. J Virol (2007) 1.62
Parasite-dependent expansion of TNF receptor II-positive regulatory T cells with enhanced suppressive activity in adults with severe malaria. PLoS Pathog (2009) 1.46
A new prognostic model for FIGO stage 1 epithelial ovarian cancer. Gynecol Oncol (2006) 1.43
LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin. Cancer Res (2012) 1.39
Investigation of a novel approach to scoring Giemsa-stained malaria-infected thin blood films. Malar J (2008) 1.35
Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: formulation of a model vaccine for respiratory syncytial virus. Mol Pharm (2007) 1.34
Role of integrin receptors for fibronectin, collagen and laminin in the regulation of ovarian carcinoma functions in response to a matrix microenvironment. Clin Exp Metastasis (2005) 1.30
An approach to remove albumin for the proteomic analysis of low abundance biomarkers in human serum. Proteomics (2003) 1.30
Antibodies to Plasmodium falciparum and Plasmodium vivax merozoite surface protein 5 in Indonesia: species-specific and cross-reactive responses. J Infect Dis (2008) 1.28
Nomogram to predict the probability of relapse in patients diagnosed with borderline ovarian tumors. Int J Gynecol Cancer (2013) 1.25
Correlation of memory T cell responses against TRAP with protection from clinical malaria, and CD4 CD25 high T cells with susceptibility in Kenyans. PLoS One (2008) 1.25
Ex vivo interferon-gamma immune response to thrombospondin-related adhesive protein in coastal Kenyans: longevity and risk of Plasmodium falciparum infection. Am J Trop Med Hyg (2003) 1.22
A regulatory role for CD37 in T cell proliferation. J Immunol (2004) 1.20
Poly-L-lysine-coated nanoparticles: a potent delivery system to enhance DNA vaccine efficacy. Vaccine (2006) 1.16
Plasmodium falciparum-mediated induction of human CD25Foxp3 CD4 T cells is independent of direct TCR stimulation and requires IL-2, IL-10 and TGFbeta. PLoS Pathog (2009) 1.14
Heroes or villains? T regulatory cells in malaria infection. Trends Parasitol (2009) 1.12
Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia. Vaccine (2004) 1.12
Methods for nano-particle based vaccine formulation and evaluation of their immunogenicity. Methods (2006) 1.11
Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance. J Cell Biochem (2013) 1.10
Vaccines that facilitate antigen entry into dendritic cells. Immunol Cell Biol (2004) 1.09
Analysis of FOXP3+ regulatory T cells that display apparent viral antigen specificity during chronic hepatitis C virus infection. PLoS Pathog (2009) 1.08
A glycopeptide in complex with MHC class I uses the GalNAc residue as an anchor. Proc Natl Acad Sci U S A (2003) 1.07
Defining target antigens for CD25+ FOXP3 + IFN-gamma- regulatory T cells in chronic hepatitis C virus infection. Immunol Cell Biol (2007) 1.06
First-line therapy in ovarian cancer trials. Int J Gynecol Cancer (2011) 1.03
Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]. Breast Cancer Res (2006) 1.03
Dendritic cells induce immunity and long-lasting protection against blood-stage malaria despite an in vitro parasite-induced maturation defect. Infect Immun (2004) 1.02
Pontocerebellar hypoplasia type 6: A British case with PEHO-like features. Am J Med Genet A (2010) 1.02
Induction of T helper type 1 and 2 responses to 19-kilodalton merozoite surface protein 1 in vaccinated healthy volunteers and adults naturally exposed to malaria. Infect Immun (2002) 1.02
Attributes of Oct4 in stem cell biology: perspectives on cancer stem cells of the ovary. J Ovarian Res (2012) 1.02
Microwave tomography of extremities: 2. Functional fused imaging of flow reduction and simulated compartment syndrome. Phys Med Biol (2011) 1.01
The impact of PET/CT in the management of recurrent ovarian cancer. Gynecol Oncol (2006) 1.00
Single coronary artery. J Am Coll Cardiol (2009) 1.00
Cellular reactivity to the p. Falciparum protein trap in adult kenyans: novel epitopes, complex cytokine patterns, and the impact of natural antigenic variation. Am J Trop Med Hyg (2006) 1.00
Hot, sweet and sticky: the glycobiology of Plasmodium falciparum. Trends Parasitol (2008) 0.99
Microwave tomography of extremities: 1. Dedicated 2D system and physiological signatures. Phys Med Biol (2011) 0.99
Malignant transformation within ovarian dermoid cysts: an audit of treatment received and patient outcomes. an Australia New Zealand gynaecological oncology group (ANZGOG) and gynaecologic cancer intergroup (GCIG) study. Int J Gynecol Cancer (2010) 0.96
Crystal structure of a non-canonical low-affinity peptide complexed with MHC class I: a new approach for vaccine design. J Mol Biol (2002) 0.96
Neuroendocrine and behavioral effects of embryonic exposure to endocrine disrupting chemicals in birds. Brain Res Rev (2007) 0.95
The activin A antagonist follistatin inhibits asthmatic airway remodelling. Thorax (2012) 0.94
Crystal structure of a non-canonical high affinity peptide complexed with MHC class I: a novel use of alternative anchors. J Mol Biol (2002) 0.94
Association between alphavbeta6 integrin expression, elevated p42/44 kDa MAPK, and plasminogen-dependent matrix degradation in ovarian cancer. J Cell Biochem (2002) 0.93
Antibodies to a single, conserved epitope in Anopheles APN1 inhibit universal transmission of Plasmodium falciparum and Plasmodium vivax malaria. Infect Immun (2013) 0.92
Growth-inhibitory antibodies are not necessary for protective immunity to malaria infection. Infect Immun (2009) 0.91
The challenge of assessing infant vaccine responses in resource-poor settings. Expert Rev Vaccines (2010) 0.90
Methods of effective conjugation of antigens to nanoparticles as non-inflammatory vaccine carriers. Methods (2013) 0.89
Outcome in women with no endocervical component on cervical cytology after treatment for high-grade cervical dysplasia. Aust N Z J Obstet Gynaecol (2009) 0.88
Systemic immune responses in sheep, induced by a novel nano-bead adjuvant. Vaccine (2005) 0.88
Dimorphic Plasmodium falciparum merozoite surface protein-1 epitopes turn off memory T cells and interfere with T cell priming. Eur J Immunol (2006) 0.88
FIGO Cancer Report 2012. Int J Gynaecol Obstet (2012) 0.87
Prognostic value of elevated preoperative serum CA125 in ovarian tumors of low malignant potential: a multinational collaborative study (ANZGOG0801). Gynecol Oncol (2012) 0.87
A complementary role for the tetraspanins CD37 and Tssc6 in cellular immunity. J Immunol (2010) 0.86
Selectively impaired CD8+ but not CD4+ T cell cycle arrest during priming as a consequence of dendritic cell interaction with plasmodium-infected red cells. J Immunol (2005) 0.86
The signalling imprints of nanoparticle uptake by bone marrow derived dendritic cells. Methods (2013) 0.86
Anxiety and depression symptoms in the 2 years following diagnosis of breast or gynaecologic cancer: prevalence, course and determinants of outcome. Support Care Cancer (2015) 0.86
The good, the bad and the ugly: how altered peptide ligands modulate immunity. Expert Opin Biol Ther (2008) 0.85
Promising particle-based vaccines in cancer therapy. Expert Rev Vaccines (2008) 0.85
Proteomic profiling of proteins associated with urokinase plasminogen activator receptor in a colon cancer cell line using an antisense approach. Proteomics (2003) 0.85
Delivery of a heterologous antigen by a registered Salmonella vaccine (STM1). FEMS Microbiol Lett (2003) 0.84
Delivery of DNA vaccines: an overview on the use of biodegradable polymeric and magnetic nanoparticles. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2010) 0.84
Incidence of microsatellite instability in synchronous tumors of the ovary and endometrium. Clin Cancer Res (2003) 0.84
An investigation into the relationship between vigabatrin, movement disorders, and brain magnetic resonance imaging abnormalities in children with infantile spasms. Dev Med Child Neurol (2013) 0.84
Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors). Int J Gynecol Cancer (2014) 0.84
Screening for depression and anxiety in women with breast and gynaecologic cancer: course and prevalence of morbidity over 12 months. Psychooncology (2013) 0.83
Interleukin-13 regulates secretion of the tumor growth factor-{beta} superfamily cytokine activin A in allergic airway inflammation. Am J Respir Cell Mol Biol (2009) 0.83
Differential uptake of nanoparticles and microparticles by pulmonary APC subsets induces discrete immunological imprints. J Immunol (2013) 0.83
Current academic clinical trials in ovarian cancer: Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting, May 2009. Int J Gynecol Cancer (2010) 0.83
A phase II trial of capecitabine in heavily pre-treated platinum-resistant ovarian cancer. Gynecol Oncol (2004) 0.83
Reducing TNF receptor 2+ regulatory T cells via the combined action of azacitidine and the HDAC inhibitor, panobinostat for clinical benefit in acute myeloid leukemia patients. Clin Cancer Res (2013) 0.83
Should the Pap smear be repeated at the first colposcopy visit? Aust N Z J Obstet Gynaecol (2005) 0.82
TNFR2 Expression on CD25(hi)FOXP3(+) T Cells Induced upon TCR Stimulation of CD4 T Cells Identifies Maximal Cytokine-Producing Effectors. Front Immunol (2013) 0.82
Induction of multi-functional T cells in a phase I clinical trial of dendritic cell immunotherapy in hepatitis C virus infected individuals. PLoS One (2012) 0.82
Re-transplantation after bortezomib-based therapy. Br J Haematol (2011) 0.82
Excessive bleeding and transfusion in a prior cardiac surgery is associated with excessive bleeding and transfusion in the next surgery. Anesth Analg (2006) 0.82
Immunological impact of an additional early measles vaccine in Gambian children: responses to a boost at 3 years. Vaccine (2012) 0.82
Complementary medicine use by Australian women with gynaecological cancer. Psychooncology (2006) 0.82
Cotyledonoid dissecting leiomyoma. Pathology (2003) 0.82
Persistent trophoblast disease following partial molar pregnancy. Aust N Z J Obstet Gynaecol (2006) 0.82
CD38 identifies a hypo-proliferative IL-13-secreting CD4+ T-cell subset that does not fit into existing naive and memory phenotype paradigms. Eur J Immunol (2011) 0.81
Inert 50-nm polystyrene nanoparticles that modify pulmonary dendritic cell function and inhibit allergic airway inflammation. J Immunol (2011) 0.81
Sister Society Meeting on Global Education Development and Collaboration: Meeting Report. Int J Gynecol Cancer (2016) 0.81
Hereditary gynecologic cancers. Int J Gynaecol Obstet (2013) 0.80
On the efficacy of malaria DNA vaccination with magnetic gene vectors. J Control Release (2013) 0.80
Question 1: Should steroids be used to treat abdominal pain caused by Henoch-Schonlein purpura? Arch Dis Child (2012) 0.80